Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H40N4O10 |
| Molecular Weight | 496.5524 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)OC[C@]1(C)O
InChI
InChIKey=BRZYSWJRSDMWLG-DJWUNRQOSA-N
InChI=1S/C20H40N4O10/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19/h6-19,24-30H,4-5,21-23H2,1-3H3/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6159822Curator's Comment: description was created based on several sources, including:
http://www.invivogen.com/g418 | http://www.g418-evopure.com/Technical.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6159822
Curator's Comment: description was created based on several sources, including:
http://www.invivogen.com/g418 | http://www.g418-evopure.com/Technical.html
Geneticin (G-418) is produced by Micromonospora phodorangea. The antibiotic has brad spectrum antibacterial activity similar to gentamicins and other previously described aminoglycosides but of particular interest because of its high activity against protozoa, amoebae, tapeworm and pinworm infections in mice. G418 blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells. G418 is commonly used in laboratory research to select genetically engineered cells.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| ATP-binding cassette transporters as pitfalls in selection of transgenic cells. | 2010-04-15 |
|
| Stop codon read-through of a methylmalonic aciduria mutation. | 2009-08 |
|
| Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. | 2009-04-01 |
|
| G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis. | 2008-09 |
|
| Restoration of W1282X CFTR activity by enhanced expression. | 2007-09 |
|
| Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. | 2006-06 |
|
| Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation. | 2006-02-10 |
|
| Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. | 2004-11-02 |
|
| Cytochrome c release and endoplasmic reticulum stress are involved in caspase-dependent apoptosis induced by G418. | 2004-07 |
|
| Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. | 2004-05-01 |
|
| Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. | 2003-09 |
|
| Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. | 2002-11 |
|
| Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. | 1998-08 |
|
| Inhibition of HIV type 1 production by hygromycin B. | 1998-07-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19150990
4 mg/kg to neonatal mice from postnatal day (PND) 5–13.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6378088
All of the Saccharomyces sp. strains, including the brewing strains, were found to be susceptible to G418 in the concentration range of 150 to 500 ug/ml. Of the three Schwanniomyces species investigated, only Schwanniomyces castellii (strain 1402) was found to be resistant to G418 at concentrations up to 1 mg/ml.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
204605
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
123865
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
DTXSID10198129
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
A08F5XTI6G
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
42768
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
G418
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
49863-47-0
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY | |||
|
DB04263
Created by
admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD